Can a new eye test match the gold standard for glaucoma?

NCT ID NCT07765147

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study compares two visual field tests used to monitor glaucoma: the current standard Humphrey Visual Field Analyzer and the newer iCare COMPASS. About 28 people with glaucoma or related eye conditions will take both tests in the same visit, with the order alternating between participants. Researchers will compare key measurements, like mean deviation and pattern deviation, to see if the iCare COMPASS provides similar accuracy and any practical advantages.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Visual field testing with the iCare COMPASS device compared to the standard Humphrey Visual Field Analyzer
What this could lead to
If the iCare COMPASS proves as accurate as the current standard, it could offer a faster or more convenient way to monitor glaucoma and other eye conditions.
What could go wrong
This is a small, early-stage comparison study, so results may not apply broadly. The new device might not match the standard's accuracy or could have practical drawbacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLAUCOMA 1, OPEN ANGLE, D (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eugene and Marilyn Glick Eye Institute

    Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.